- Home
- ADVB vs MRKR Comparison
ADVB vs MRKR Comparison
Compare ADVB & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVB
- MRKR
- Stock Information
- Founded
- ADVB 2014
- MRKR N/A
- Country
- ADVB United States
- MRKR United States
- Employees
- ADVB N/A
- MRKR N/A
- Industry
- ADVB Medical Specialities
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- ADVB Health Care
- MRKR Health Care
- Exchange
- ADVB Nasdaq
- MRKR Nasdaq
- Market Cap
- ADVB 20.8M
- MRKR 19.1M
- IPO Year
- ADVB 2025
- MRKR N/A
- Fundamental
- Price
- ADVB $0.69
- MRKR $1.45
- Analyst Decision
- ADVB
- MRKR Strong Buy
- Analyst Count
- ADVB 0
- MRKR 3
- Target Price
- ADVB N/A
- MRKR $13.17
- AVG Volume (30 Days)
- ADVB 57.0K
- MRKR 235.1K
- Earning Date
- ADVB 08-03-2025
- MRKR 08-13-2025
- Dividend Yield
- ADVB N/A
- MRKR N/A
- EPS Growth
- ADVB N/A
- MRKR N/A
- EPS
- ADVB N/A
- MRKR N/A
- Revenue
- ADVB N/A
- MRKR $5,696,123.00
- Revenue This Year
- ADVB N/A
- MRKR N/A
- Revenue Next Year
- ADVB N/A
- MRKR $11.28
- P/E Ratio
- ADVB N/A
- MRKR N/A
- Revenue Growth
- ADVB N/A
- MRKR 71.53
- 52 Week Low
- ADVB $0.69
- MRKR $0.95
- 52 Week High
- ADVB $4.10
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- ADVB N/A
- MRKR 50.31
- Support Level
- ADVB N/A
- MRKR $1.46
- Resistance Level
- ADVB N/A
- MRKR $1.94
- Average True Range (ATR)
- ADVB 0.00
- MRKR 0.20
- MACD
- ADVB 0.00
- MRKR -0.02
- Stochastic Oscillator
- ADVB 0.00
- MRKR 40.24
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.